Soonmyung Paik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2245284/publications.pdf

Version: 2024-02-01

94 papers	37,369 citations	43973 48 h-index	40881 93 g-index
96 all docs	96 docs citations	96 times ranked	29469 citing authors

#	Article	IF	Citations
1	Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.. Journal of Clinical Oncology, 2022, 40, 603-603.	0.8	1
2	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. European Journal of Cancer, 2021, 143, 113-126.	1.3	30
3	Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. Npj Breast Cancer, 2021, 7, 13.	2.3	10
4	Genomic landscape of extraordinary responses in metastatic breast cancer. Communications Biology, 2021, 4, 449.	2.0	3
5	Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Scientific Reports, 2021, 11, 20263.	1.6	11
6	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. JAMA Oncology, 2020, 6, 367.	3.4	100
7	Genomic profiling of the residual disease of advanced highâ€grade serous ovarian cancer after neoadjuvant chemotherapy. International Journal of Cancer, 2020, 146, 1851-1861.	2.3	19
8	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology, 2020, 38, 444-453.	0.8	234
9	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectrum, 2020, 4, pkaa058.	1.4	2
10	Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. IScience, 2020, 23, 101386.	1.9	5
11	An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier. Cancers, 2020, 12, 3506.	1.7	9
12	Mouseâ€“human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. British Journal of Cancer, 2020, 123, 1720-1729.	2.9	18
13	Destabilization of Î²-catenin and RAS by targeting the Wnt/Î²-catenin pathway as a potential treatment for triple-negative breast cancer. Experimental and Molecular Medicine, 2020, 52, 832-842.	3.2	21
14	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Scientific Reports, 2020, 10, 9050.	1.6	43
15	Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer. BMC Cancer, 2020, 20, 316.	1.1	14
16	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology, 2019, 37, 3425-3435.	0.8	51
17	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	13.9	349
18	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 867-871.	3.0	41

#	Article	IF	Citations
19	A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both Î²-Catenin and RAS. Cancers, 2019, 11, 496.	1.7	9
20	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Research, 2019, 21, 133.	2.2	30
21	PI3K/AKT/Î²-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. Cancers, 2019, 11, 1923.	1.7	22
22	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, The, 2019, 394, 2155-2164.	6.3	319
23	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq1 1 0.784314 rgBT /Overlock 1 The, 2019, 20, 88-99.	5.1	108
24	Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	9	
25	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. Cancer Research and Treatment, 2019, 51, 1527-1539.	1.3	5
26	Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Research, 2018, 28, 374-382.	2.4	59
27	AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing. Bioinformatics, 2018, 34, 1232-1234.	1.8	3
28	Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). British Journal of Cancer, 2018, 118, 629-633.	2.9	18
29	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment, 2018, 168, 69-77.	1.1	36
30	21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Npj Breast Cancer, 2018, 4, 37.	2.3	65
31	Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer. British Journal of Cancer, 2018, 119, 1347-1357.	2.9	18
32	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenetics and Genomics, 2018, 28, 147-152.	0.7	4
33	Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology, 2018, 155, 799-814.e13.	0.6	83
34	Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS ONE, 2018, 13, e0200836.	1.1	8
35	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Lung Cancer, 2018, 124, 168-178.	0.9	23
36	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	13.9	1,558

#	Article	IF	Citations
37	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 163, 255-262.	1.1	3
38	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
39	21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. Journal of the National Cancer Institute, 2017, 109, djw259.	3.0	116
40	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2â€“Positive Breast Cancer. JAMA Oncology, 2017, 3, 335.	3.4	96
41	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology, 2017, 24, 1853-1860.	0.7	8
42	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget, 2017, 8, 38389-38398.	0.8	8
43	Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Oncotarget, 2017, 8, 39367-39381.	0.8	38
44	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptorâ€“Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. Journal of Clinical Oncology, 2016, 34, 2350-2358.	0.8	71
45	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600Eâ€“Mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2016, 15, 1627-1636.	1.9	8
46	Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes. JAMA Oncology, 2016, 2, 1162.	3.4	140
47	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. New England Journal of Medicine, 2016, 374, 211-222.	13.9	388
48	Prognostic Tests for Estrogen Receptorâ€“Positive Breast Cancer. JAMA Oncology, 2016, 2, 180.	3.4	1
49	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget, 2016, 7, 24172-24178.	0.8	41
50	Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Medical Journal, 2015, 56, 1186.	0.9	14
51	Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls. Journal of Clinical Oncology, 2015, 33, 3671-3672.	0.8	5
52	Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of Clinical Oncology, 2015, 33, 1340-1347.	0.8	105
53	A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Research and Treatment, 2015, 149, 517-523.	1.1	22
54	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clinical Cancer Research, 2015, 21, 544-552.	3.2	56

#	Article	IF	Citations
55	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2015, 14, 2238-2248.	1.9	19
56	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	0.6	177
57	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2015, 373, 2005-2014.	13.9	1,146
58	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1037-1048.	5.1	138
59	Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chemical Reviews, 2015, 115, 327-394.	23.0	1,063
60	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 44971-44984.	0.8	13
61	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
62	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. Journal of Clinical Oncology, 2014, 32, 3507-3507.	0.8	53
63	NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC.. Journal of Clinical Oncology, 2014, 32, TPS1141-TPS1141.	0.8	31
64	Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31. Journal of the National Cancer Institute, 2013, 105, 1782-1788.	3.0	94
65	Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin. Journal of Clinical Oncology, 2013, 31, 4512-4519.	0.8	155
66	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
67	Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. Journal of the National Cancer Institute, 2013, 105, 989-992.	3.0	56
68	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery, 2013, 3, 812-825.	7.7	61
69	Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. Clinical Cancer Research, 2012, 18, 6531-6541.	3.2	272
70	Is gene array testing to be considered routine now?. Breast, 2011, 20, S87-S91.	0.9	49
71	Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Research and Treatment, 2011, 127, 133-142.	1.1	176
72	Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4160-4167.	0.8	120

#	Article	IF	Citations
73	Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute, 2011, 103, 1559-1560.	3.0	2
74	Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptorâ€“Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20. Journal of Clinical Oncology, 2010, 28, 1677-1683.	0.8	538
75	A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer, 2010, 10, 101.	1.1	115
76	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	0.8	2,667
77	Gene-expression-based prognostic assays for breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 340-347.	12.5	146
78	Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute, 2009, 101, 1446-1452.	3.0	899
79	Gene Expressionâ€“Based Prognostic and Predictive Markers for Breast Cancer: A Primer for Practicing Pathologists. Archives of Pathology and Laboratory Medicine, 2009, 133, 855-859.	1.2	18
80	HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. New England Journal of Medicine, 2008, 358, 1409-1411.	13.9	416
81	Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. Journal of Clinical Oncology, 2008, 26, 721-728.	0.8	536
82	Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology, 2008, 26, 778-785.	0.8	1,524
83	Development and Clinical Utility of a 21â€Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen. Oncologist, 2007, 12, 631-635.	1.9	167
84	Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 3726-3734.	0.8	2,369
85	Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization. Methods, 2006, 38, 253-262.	1.9	26
86	Assays for Gene Amplification. , 2006, , 65-77.		0
87	Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 2006, 24, 2019-2027.	0.8	850
88	Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nature Clinical Practice Oncology, 2005, 2, 246-254.	4.3	85
89	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1673-1684.	13.9	4,956
90	A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine, 2004, 351, 2817-2826.	13.9	5,646

#	Article	IF	Citations
91	Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnology Annual Review, 2003, 9, 259-267.	2.1	18
92	Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. Journal of the National Cancer Institute, 2002, 94, 852-854.	3.0	463
93	HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. Journal of the National Cancer Institute, 2000, 92, 1991-1998.	3.0	258
94	erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor-Negative Breast Cancer. Journal of the National Cancer Institute, 1998, 90, 1361-1370.	3.0	620